Back to search results

Solid Tumor

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

JLDA | {{ defaultRegistry.registryAnchorText }} NCT03099109 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participants with advanced relapsed/refractory solid tumors.

Time Commitment

Your participation could last up to 12 months depending on how you and your tumor respond

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


18+ years
  • Participant must have an advanced solid tumor confirmed by histology or cytology
  • Phase 1a participant must submit an archived tumor tissue sample (if available)
  • Phase 1b participant must be willing to provide a new or recently obtained biopsy
  • Participant must have an estimated life expectancy of 12 weeks
  • Participant must not have symptoms of uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease that requires treatment occurring at the same time as the study treatment
  • Participant must not have received a live vaccine within 30 days before the first dose of study treatment
  • Female participant must not be pregnant, breastfeeding, or planning to become pregnant
  • Participant must not have active or chronic HIV, active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment
  • Participant must not have a bowel obstruction

Where to Participate

Where to Participate

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.